https://www.selleckchem.com/products/lf3.html
The main purpose of this study was to investigate the effects of 12months of rhPTH (1-84) (Natpar ) treatment in a cohort of patients selected according to the indications of hypoparathyroidism guidelines. The use of recombinant human PTH (1-84) [rhPTH (1-84)] is approved as hormonal replacement therapy in patients with hypoparathyroidism not adequately controlled with conventional therapy. It is a multicenter, observational, retro-prospective, open label study. Eleven Italian Endocrinological centers, members of Hypoparathyroidism Working
Like
Comment
Share
